Work Here?
Overview
Landmark Bio is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. It provides end-to-end services including drug development consulting, process analytical development, cGMP manufacturing, and CMC regulatory consulting to turn research into clinical programs. Its offerings are tailored services rather than products, delivered through collaborations with academia, physicians, biopharma, and research hospitals to address manufacturing costs and complexities. Its goal is to help programs reach clinical trials and commercial use faster while meeting regulatory standards and budget constraints, increasing patient access to advanced therapies.
About Landmark Bio
Industries
Consulting
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Watertown, Massachusetts
Founded
N/A
Simplify's Take
What believers are saying
- Artis BioSolutions acquisition on April 2, 2025, expands end-to-end preclinical to commercial solutions.
- ARPA-H award integrates advanced upstream, downstream technologies to overcome batch limitations.
- Deep expertise from 150 tech transfers, 46 BLAs, and 45 approved products attracts biopharma clients.
What critics are saying
- Larger CDMOs like Catalent and Lonza erode market share in 12-24 months.
- Galapagos terminates CAR-T contract after batch failures in 6-12 months.
- Artis diverts resources from Landmark within 3-6 months post-acquisition.
What makes Landmark Bio unique
- Landmark Bio offers modular cGMP suites for LVV, AAV, cell processing, mRNA, and novel modalities.
- Secured up to $18.3M ARPA-H funding on April 1, 2026, for continuous EV manufacturing platform.
- Signed manufacturing agreement with Galapagos for oncology CAR-T cell therapy.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Unlimited Paid Time Off
Flexible Work Hours
Hybrid Work Options
Professional Development Budget
Conference Attendance Budget
Wellness Program
Mental Health Support
Stock Options
Company Equity
401(k) Retirement Plan
401(k) Company Match
Phone/Internet Stipend
Home Office Stipend
Company News
Artis BioSolutions has appointed Dr Kate Broderick as Chief Scientific Innovation Officer, effective 9 February 2026. She will lead scientific strategy and innovation initiatives across the company's platform for developing and manufacturing genetic medicines. Dr Broderick brings over 25 years of experience in nucleic acid medicine and DNA- and RNA-based vaccine development. Most recently, she served as Chief Innovation Officer at Maravai LifeSciences. Previously, at Inovio Pharmaceuticals, she led R&D teams that advanced multiple clinical-stage programmes, including a DNA-based COVID-19 vaccine through Phase 3 testing, and secured over $100 million in non-dilutive funding. The appointment comes as Artis prepares to close its acquisition of Syngoi Technologies, expected in the first quarter of 2026. Dr Broderick holds a PhD in Molecular Genetics from the University of Glasgow.
Artis BioSolutions, a company founded to streamline the discovery, development and production of genetic medicines, today announced its launch, alongside its...
Landmark Bio is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Landmark Bio
Industries
Consulting
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Watertown, Massachusetts
Founded
N/A
Landmark Bio is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today